In spite of the potential of biosensors and their wide application in research, only some chips have
entered the clinical market. Among these are the glucose sensors that were leading the market until a
few years ago: 6% of the Western world population is, in fact, affected by diabetes and would benefit
from the availability of rapid, accurate and simple biosensor for glucose. Nowadays, however, there is
a great demand for monitoring other molecules such us cholesterol, lactate, urea, creatine, that are very
important markers for health care. The reason for this limited adoption of biosensors in the market is
that many critical parameters, such as quality control and selection of testing parameters and control
need to be improved. Moreover, new projected biosensors have to meet the need that were not
accomplished by the existing analyzers and have to provide some distinct advantage, for example
improved ease of use, faster response time and portability.